Compare NKSH & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | SLN |
|---|---|---|
| Founded | 1891 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 236.2M |
| IPO Year | 1995 | N/A |
| Metric | NKSH | SLN |
|---|---|---|
| Price | $36.80 | $6.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 56.3K | ★ 330.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $24.74 | $4.19 |
| 52 Week High | $40.00 | $8.40 |
| Indicator | NKSH | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 50.45 |
| Support Level | $27.59 | $5.91 |
| Resistance Level | $35.00 | $7.21 |
| Average True Range (ATR) | 1.43 | 0.46 |
| MACD | -0.19 | -0.12 |
| Stochastic Oscillator | 0.56 | 32.12 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.